Noul Showcases AI Cervical Cancer Screening at NVIDIA GTC 2025

Noul Co., Ltd. presented its AI-powered cervical cancer screening technology at NVIDIA GTC 2025, highlighting its miLab™ CER platform.

Noul Co., Ltd. showcased its AI-powered cervical cancer screening technology at the NVIDIA GTC 2025 conference. Announced in a press release, the company presented a poster titled "Bridging Medical Gaps from Malaria to Cancer: On-Device AI Diagnostic Solutions Powered by NVIDIA Jetson," highlighting its miLab™ CER platform.

The miLab™ CER is a compact, fully automated diagnostic device that performs sample staining, digital imaging, and AI-powered result analysis, delivering results in just 15 minutes. This platform, powered by NVIDIA Jetson, aims to improve diagnostic accessibility in underserved regions and centralized healthcare systems.

Noul's participation in the NVIDIA Healthcare & Life Sciences partner ecosystem marks a significant step in advancing AI's role in global healthcare delivery. The miLab™ CER platform was previously recognized by WHO-UNITAID as one of the top global diagnostic products for cervical cancer triage.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following our LinkedIn page AI Brief.

More from: Healthcare & Life Sciences

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like